ucsf logobch logo

Laura Deering, MD

Pediatric Neurology • Neurology
Neuromuscular Parnassus
415-353-2273
Portrait of Laura Deering
Portrait of Laura Deering
ucsf logobch logo

Laura Deering, MD

Pediatric Neurology • Neurology
Neuromuscular Parnassus
415-353-2273

On this page

About me

Dr. Laura Deering is a neurologist and neuromuscular specialist who cares for children and young adults with neuromuscular conditions (affecting the nerves and muscles), including muscular dystrophy, myopathy, spinal muscular atrophy, Charcot-Marie-Tooth disease and myasthenia gravis.

She has particular expertise in performing electromyography - including single fiber studies ¬- to diagnose disorders of the nerves, muscles and neuromuscular junction (the connection between the nerves and muscles). She is particularly interested in collaborating across specialties to support the best quality of life possible for patients.

In her research, Deering focuses on developing new therapies for children with neuromuscular disorders and leukodystrophies.

Deering earned her medical degree at Weill Cornell Medicine. She completed a residency in child neurology and a fellowship in neuromuscular medicine at UCSF.

Education & training

Board certification

  • Neurology with Special Qualification in Child Neurology, American Board of Psychiatry and Neurology

Fellowship

  • Neuromuscular Medicine, UCSF School of Medicine -GME

Residency

  • Child Neurology, UCSF School of Medicine -GME

Internship

  • Pediatrics, UCSF School of Medicine -GME

Degree

  • MD, Weill Cornell Medical College

My expertise

Locations

    My research

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.